[1]
Gallagher JC, Dodds Ashley ES, Drew RH, Perfect JR. Antifungal pharmacotherapy for invasive mould infections. Expert opinion on pharmacotherapy. 2003 Feb:4(2):147-64
[PubMed PMID: 12562305]
Level 3 (low-level) evidence
[2]
Peyton LR, Gallagher S, Hashemzadeh M. Triazole antifungals: a review. Drugs of today (Barcelona, Spain : 1998). 2015 Dec:51(12):705-18. doi: 10.1358/dot.2015.51.12.2421058. Epub
[PubMed PMID: 26798851]
[3]
Heeres J, Meerpoel L, Lewi P. Conazoles. Molecules (Basel, Switzerland). 2010 Jun 9:15(6):4129-88. doi: 10.3390/molecules15064129. Epub 2010 Jun 9
[PubMed PMID: 20657432]
[4]
Poojary S, Miskeen A, Bagadia J, Jaiswal S, Uppuluri P. A Study of In vitro Antifungal Susceptibility Patterns of Dermatophytic Fungi at a Tertiary Care Center in Western India. Indian journal of dermatology. 2019 Jul-Aug:64(4):277-284. doi: 10.4103/ijd.IJD_456_18. Epub
[PubMed PMID: 31516136]
[5]
Rauseo AM, Mazi P, Lewis P, Burnett B, Mudge S, Spec A. Bioavailability of Single-Dose SUBA-Itraconazole Compared to Conventional Itraconazole under Fasted and Fed Conditions. Antimicrobial agents and chemotherapy. 2021 Jul 16:65(8):e0013421. doi: 10.1128/AAC.00134-21. Epub 2021 Jul 16
[PubMed PMID: 34031053]
[6]
Hoy SM. Oteseconazole: First Approval. Drugs. 2022 Jun:82(9):1017-1023. doi: 10.1007/s40265-022-01734-y. Epub
[PubMed PMID: 35713845]
[7]
Patel T, Dhillon S. Efinaconazole: first global approval. Drugs. 2013 Nov:73(17):1977-83. doi: 10.1007/s40265-013-0152-x. Epub
[PubMed PMID: 24249649]
[8]
Shirley M, Scott LJ. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis. Drugs. 2016 Nov:76(17):1647-1657
[PubMed PMID: 27766566]
[9]
Hussain MK, Ahmed S, Khan A, Siddiqui AJ, Khatoon S, Jahan S. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents. European journal of medicinal chemistry. 2023 Jan 15:246():115010. doi: 10.1016/j.ejmech.2022.115010. Epub 2022 Dec 10
[PubMed PMID: 36566630]
[10]
Wang X, Chen L, Ruan H, Xiong Z, Wang W, Qiu J, Song W, Zhang C, Xue F, Qin T, Zhang B, An R, Luo X, Wang W, Zhang S, Cai Y, Kang J, Deng H, Fan S, Cui M, Wang S, Luo X, Su Z, Shu J, Wang Q, Wang F, Bai J, Liao Q. Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial. Antimicrobial agents and chemotherapy. 2024 Jan 10:68(1):e0077823. doi: 10.1128/aac.00778-23. Epub 2023 Dec 14
[PubMed PMID: 38095426]
Level 1 (high-level) evidence
[11]
Zonios DI, Bennett JE. Update on azole antifungals. Seminars in respiratory and critical care medicine. 2008 Apr:29(2):198-210. doi: 10.1055/s-2008-1063858. Epub
[PubMed PMID: 18366001]
[12]
Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clinical pharmacokinetics. 2008:47(12):779-92. doi: 10.2165/0003088-200847120-00003. Epub
[PubMed PMID: 19026034]
[13]
Albengres E, Le Louët H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug safety. 1998 Feb:18(2):83-97
[PubMed PMID: 9512916]
[14]
Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, Pappagianis D, Stevens DA. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1992 Jan:14(1):165-74
[PubMed PMID: 1315160]
[15]
Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y. Blockade of HERG cardiac K+ current by antifungal drug miconazole. British journal of pharmacology. 2005 Mar:144(6):840-8
[PubMed PMID: 15778703]
[16]
Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017 Dec:45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12
[PubMed PMID: 28702763]
[17]
Sardana K, Mathachan SR. Super Bioavailable Itraconazole and Its Place and Relevance in Recalcitrant Dermatophytosis: Revisiting Skin Levels of Itraconazole and Minimum Inhibitory Concentration Data. Indian dermatology online journal. 2021 Jan-Feb:12(1):1-5. doi: 10.4103/idoj.IDOJ_618_20. Epub 2021 Jan 16
[PubMed PMID: 33768016]
[18]
Regidor PA, Thamkhantho M, Chayachinda C, Palacios S. Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2023 Dec:43(1):2195001. doi: 10.1080/01443615.2023.2195001. Epub
[PubMed PMID: 37029724]
[19]
Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Mar 15:48(6):839. doi: 10.1086/597110. Epub
[PubMed PMID: 19220151]
[20]
Zhou ZX, Yin XD, Zhang Y, Shao QH, Mao XY, Hu WJ, Shen YL, Zhao B, Li ZL. Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database. Frontiers in pharmacology. 2022:13():891336. doi: 10.3389/fphar.2022.891336. Epub 2022 Apr 28
[PubMed PMID: 35571077]
[21]
Oude Lashof AM, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Rex JH, Kullberg BJ. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrobial agents and chemotherapy. 2012 Jun:56(6):3133-7. doi: 10.1128/AAC.05841-11. Epub 2012 Mar 26
[PubMed PMID: 22450974]
[22]
Stott KE, Hope WW. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. The Journal of antimicrobial chemotherapy. 2017 Mar 1:72(suppl_1):i12-i18. doi: 10.1093/jac/dkx029. Epub
[PubMed PMID: 28355463]
[23]
Mogensen DM, Pihl MB, Skakkebæk NE, Andersen HR, Juul A, Kyhl HB, Swan S, Kristensen DM, Andersen MS, Lind DV, Jensen TK. Prenatal exposure to antifungal medication may change anogenital distance in male offspring: a preliminary study. Environmental health : a global access science source. 2017 Jun 21:16(1):68. doi: 10.1186/s12940-017-0263-z. Epub 2017 Jun 21
[PubMed PMID: 28637461]
[24]
Patel MA, Aliporewala VM, Patel DA. Common Antifungal Drugs in Pregnancy: Risks and Precautions. Journal of obstetrics and gynaecology of India. 2021 Dec:71(6):577-582. doi: 10.1007/s13224-021-01586-8. Epub 2021 Nov 9
[PubMed PMID: 34898894]
[28]
Dekkers BGJ, Veringa A, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar JC. Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. Drugs & aging. 2018 Sep:35(9):781-789. doi: 10.1007/s40266-018-0576-9. Epub
[PubMed PMID: 30047069]
[29]
Mayer UK, Glos K, Schmid M, Power HT, Bettenay SV, Mueller RS. Adverse effects of ketoconazole in dogs--a retrospective study. Veterinary dermatology. 2008 Aug:19(4):199-208. doi: 10.1111/j.1365-3164.2008.00675.x. Epub
[PubMed PMID: 18547382]
Level 2 (mid-level) evidence
[30]
Gu TM, Lewis JS 2nd, Le H, Bubalo JS. Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2022 Sep:28(6):1357-1362. doi: 10.1177/10781552211029046. Epub 2021 Jul 1
[PubMed PMID: 34192963]
Level 2 (mid-level) evidence
[31]
Chen W, Wu T, Jiang S, Lv M, Fu J, Xia X, Zhang J. Clinical analysis of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Medicine. 2020 Nov 13:99(46):e22987. doi: 10.1097/MD.0000000000022987. Epub
[PubMed PMID: 33181661]
[32]
Yang J, Atkins WM, Isoherranen N, Paine MF, Thummel KE. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clinical pharmacology and therapeutics. 2012 Mar:91(3):442-9. doi: 10.1038/clpt.2011.178. Epub 2011 Nov 2
[PubMed PMID: 22048224]
[33]
Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clinical pharmacokinetics. 2004:43(11):725-32
[PubMed PMID: 15301576]
[34]
Dybro AM, Damkier P, Rasmussen TB, Hellfritzsch M. Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole. BMJ case reports. 2016 Sep 7:2016():. doi: 10.1136/bcr-2016-216457. Epub 2016 Sep 7
[PubMed PMID: 27605198]
Level 3 (low-level) evidence
[35]
Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clinical pharmacology and therapeutics. 2001 Sep:70(3):247-54
[PubMed PMID: 11557912]
[36]
Carreras E, Dufour C, Mohty M, Kröger N, Bauters T. Clinically Relevant Drug Interactions in HSCT. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019:():
[PubMed PMID: 32091802]
[37]
Azanza JR, Mensa J, Barberán J, Vázquez L, Pérez de Oteyza J, Kwon M, Yáñez L, Aguado JM, Cubillo Gracian A, Solano C, Ruiz Camps I, Fortún J, Salavert Lletí M, Gudiol C, Olave Rubio T, Solano C, García-Vidal C, Rovira Tarrats M, Suárez-Lledó Grande M, González-Sierra P, Dueñas Gutiérrez C. Recommendations on the use of azole antifungals in hematology-oncology patients. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2023 Jun:36(3):236-258. doi: 10.37201/req/013.2023. Epub 2023 Apr 5
[PubMed PMID: 37017117]
[38]
Shumaker AC, Bullard HM, Churpek J, Knoebel RW. Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019 Oct:25(7):1758-1761. doi: 10.1177/1078155218801055. Epub 2018 Sep 27
[PubMed PMID: 30259783]
[39]
Calogiuri G, Garvey LH, Nettis E, Romita P, Di Leo E, Caruso R, Butani L, Foti C. Skin Allergy to Azole Antifungal Agents for Systemic Use: A Review of the Literature. Recent patents on inflammation & allergy drug discovery. 2019:13(2):144-157. doi: 10.2174/1872213X13666190919162414. Epub
[PubMed PMID: 31538908]
[41]
Okuyan H, Altın C. Heart failure induced by itraconazole. Indian journal of pharmacology. 2013 Sep-Oct:45(5):524-5. doi: 10.4103/0253-7613.117751. Epub
[PubMed PMID: 24130392]
[42]
Bhat VS, Hester SD, Nesnow S, Eastmond DA. Concordance of transcriptional and apical benchmark dose levels for conazole-induced liver effects in mice. Toxicological sciences : an official journal of the Society of Toxicology. 2013 Nov:136(1):205-15. doi: 10.1093/toxsci/kft182. Epub 2013 Aug 22
[PubMed PMID: 23970803]
[43]
Yan JY, Nie XL, Tao QM, Zhan SY, Zhang YD. Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis. Biomedical and environmental sciences : BES. 2013 Jul:26(7):605-10. doi: 10.3967/0895-3988.2013.07.013. Epub
[PubMed PMID: 23895707]
Level 1 (high-level) evidence
[44]
Armstrong-James D. Future Directions for Clinical Respiratory Fungal Research. Mycopathologia. 2021 Oct:186(5):685-696. doi: 10.1007/s11046-021-00579-5. Epub 2021 Sep 29
[PubMed PMID: 34590208]
Level 3 (low-level) evidence
[45]
Kajfasz P, Basiak W. Outbreak of pulmonary histoplasmosis involving a group of four Polish travellers returning from Ecuador. International maritime health. 2012:63(1):59-62
[PubMed PMID: 22669814]
[46]
Kara E, Metan G, Bayraktar-Ekincioglu A, Gulmez D, Arikan-Akdagli S, Demirkazik F, Akova M, Unal S, Uzun O. Implementation of Pharmacist-Driven Antifungal Stewardship Program in a Tertiary Care Hospital. Antimicrobial agents and chemotherapy. 2021 Aug 17:65(9):e0062921. doi: 10.1128/AAC.00629-21. Epub 2021 Aug 17
[PubMed PMID: 34152808]